<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03434275</url>
  </required_header>
  <id_info>
    <org_study_id>REC-17-025</org_study_id>
    <nct_id>NCT03434275</nct_id>
  </id_info>
  <brief_title>Evaluation of Preoperative N1539 in Total Knee Arthroplasty</brief_title>
  <official_title>A Phase 3b, Randomized, Double-Blind, Placebo-Control, Multicenter, Evaluation of the Safety and Efficacy of N1539 Administered Preoperatively in Open Unilateral Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Recro Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Recro Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the effect of preoperative administration of&#xD;
      N1539 on opioid consumption in subjects undergoing open unilateral total knee arthroplasty&#xD;
      compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 19, 2018</start_date>
  <completion_date type="Actual">May 21, 2019</completion_date>
  <primary_completion_date type="Actual">May 21, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid Use Hour 0-24</measure>
    <time_frame>Up to 24 Hours</time_frame>
    <description>Total use of opioid analgesia, in IV morphine equivalent dose, from Hour 0 through 24.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">194</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>N1539 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N1539 (meloxicam injection for IV use) 30 mg every 24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV Placebo every 24 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N1539</intervention_name>
    <description>Once Daily</description>
    <arm_group_label>N1539 30 mg</arm_group_label>
    <other_name>Intravenous meloxicam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once Daily</description>
    <arm_group_label>IV Placebo</arm_group_label>
    <other_name>Intravenous placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Voluntarily provide written informed consent.&#xD;
&#xD;
          -  Be planned to undergo an elective, primary (no repeat arthroplasties) open unilateral&#xD;
             total knee arthroplasty (TKA), and be expected to require IV analgesia, remain in an&#xD;
             inpatient setting for ≥24 hours, and receive at least two doses of study drug.&#xD;
&#xD;
          -  ASA physical status category 1, 2, or 3.&#xD;
&#xD;
          -  Female subjects not pregnant or planning/attempting to become pregnant, not lactating;&#xD;
             or commits to the use of an acceptable form of birth control for the duration of the&#xD;
             study.&#xD;
&#xD;
          -  Have a body mass index &lt;40 kg/m^2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a known allergy or hypersensitivity to any study treatment.&#xD;
&#xD;
          -  Have a history of previous TKA.&#xD;
&#xD;
          -  Has plans for a concurrent surgical procedure (eg, bilateral TKA).&#xD;
&#xD;
          -  Has TKA planned to be performed under general anesthesia.&#xD;
&#xD;
          -  Have a history of myocardial infarction within the preceding 12 months.&#xD;
&#xD;
          -  Have, as determined by the investigator or the sponsor's medical monitor, a history or&#xD;
             clinical manifestations of significant condition that would preclude participation.&#xD;
&#xD;
          -  Have active or recent (within 6 months) gastrointestinal ulceration or bleeding.&#xD;
&#xD;
          -  Have a known bleeding disorder which may be worsened with the administration of an&#xD;
             NSAID.&#xD;
&#xD;
          -  Be currently receiving treatment with oral meloxicam (Mobic®) or another NSAID within&#xD;
             48 hours prior to surgery.&#xD;
&#xD;
          -  Have previously received N1539/IV meloxicam or received any investigational product&#xD;
             within 30 days before dosing with study medication.&#xD;
&#xD;
          -  Have undergone or be expected to undergo radiation therapy, chemotherapy, or other&#xD;
             biological therapy for cancer treatment, within 60 days prior to screening through&#xD;
             last follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Florence</city>
        <state>Alabama</state>
        <zip>35630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <zip>35660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>February 9, 2018</study_first_submitted>
  <study_first_submitted_qc>February 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2018</study_first_posted>
  <last_update_submitted>November 11, 2019</last_update_submitted>
  <last_update_submitted_qc>November 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Total Knee Arthroplasty</keyword>
  <keyword>Pain</keyword>
  <keyword>Analgesia</keyword>
  <keyword>N1539</keyword>
  <keyword>Phase 3b</keyword>
  <keyword>Knee Replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meloxicam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

